Triazolone compounds as mPGES-1 inhibitors

US10821100B2 · kind B2 · utility

Assignee

• Ichnos Sciences SA. · CH

Inventors

• Laxmikant A. Gharat · Jamkhed, IN
• Nagarajan Muthukaman · Erode, IN
• Neelima Khairatkar-Joshi · Thane, IN
• Vidya Ganapati Kattige · Thane, IN

Key dates

• Filing date: May 28, 2019
• Grant date: Nov 3, 2020
• Expiry date: May 28, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.